Robert Lally's departure as Senior Vice President of ImageneBio, Inc. was reported, effective July 22, 2026; the filing names no successor. As of November 6, 2026, ImageneBio, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 26, 2026 to July 23, 2026, naming 1 departure (Form 8-K, June 26, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like ImageneBio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
ImageneBio, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-26 to 2026-07-23. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as ImageneBio, Inc. files it.
Also on the record for ImageneBio, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 9.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 9.9% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by Blue Owl Capital Holdings LP | 8.51% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13D/A, by ORBIMED ADVISORS LLC | 13.1% of the class | 5%+ stakes | Source |
| April 21, 2026 | Stake report, Schedule 13D, by Omega Fund VI, L.P. | 8.4% of the class | 5%+ stakes | Source |
| April 21, 2026 | Stake report, Schedule 13G, by Trails Edge Capital Partners, LP | 9.9% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | — | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G, by Blue Owl Capital Holdings LP | 7.37% of the class | 5%+ stakes | Source |
| January 6, 2026 | Stake report, Schedule 13G, by Funicular Funds, LP | 5.8% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Blue Owl Capital Holdings LP | 4.84% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 7.2% of the class | 5%+ stakes | Source |
| August 4, 2025 | Stake report, Schedule 13G, by Deep Track Capital, LP | 7.86% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs ImageneBio, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on ImageneBio, Inc. and the records around it.
The people at ImageneBio, Inc.
- Jean-Francois Formela is also named on 1 other Form D filing: Antares Therapeutics, Inc. (May 2025)
ImageneBio, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Atlas Venture Fund X, L.P. also filed stake reports on 5 other companies: Kymera Therapeutics, Inc. (Aug 2026), Obsidian Therapeutics, Inc. (Aug 2026), Q32 Bio Inc. (May 2026)
- Blue Owl Capital Holdings LP also filed stake reports on 10 other companies: Context Therapeutics Inc. (Aug 2026), enGene Therapeutics Inc. (Aug 2026), Aktis Oncology, Inc. (May 2026)
- Funicular Funds, LP also filed stake reports on 10 other companies: AmpliTech Group, Inc. (Oct 2026), SYNLOGIC, INC. (Jul 2026), Rein Therapeutics, Inc. (May 2026)
Watch ImageneBio, Inc.
Get an email when ImageneBio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on ImageneBio, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on ImageneBio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ImageneBio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 17 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-23 | Reported | not named in the filing | 8-K, 2026-07-23 | ||
| 2026-06-26 | Out | Senior Vice President | 2026-07-22 | 8-K, 2026-06-26 |
Who leads ImageneBio, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Senior Vice President: Robert Lally, departure reported, effective 2026-07-22 (filed 2026-06-26). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on ImageneBio, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Senior Vice President at ImageneBio, Inc., with the record behind each one.
Find candidates like Senior Vice President at ImageneBio, Inc.Every change, in the filing's words
Reported
On July 20, 2026, ImageneBio, Inc., a Delaware corporation (the "Company"), based in part on the recommendation of Kristin Yarema, Ph.D., the Company's Chief Executive Officer, appointed Yanina Grant-Huerta as the Company's Chief Financial Officer, principal financial officer and principal accounting officer, effective July 20, 2026.
- Kristin Yarema, Ph.D., the Company's Chief Executive Officer, had been serving as the interim principal financial officer of the Company until the appointment of Ms. Grant-Huerta.
- Ms. Grant-Huerta, age 49, previously worked at Atara Biotherapeutics, Inc. (Nasdaq: ATRA) from April 2020 until July 2026.
- During Ms. Grant-Huerta's time at Atara Biotherapeutics, she served in various financial planning and analysis and accounting roles of increasing responsibility, most recently serving as Chief Accounting Officer from March 2025 to July 2026.
- Prior to joining Atara Biotherapeutics in April 2020, Ms. Grant-Huerta spent 14 years at Amgen Inc. holding roles of increasing responsibility in financial planning and analysis.
- Yanina Grant-Huerta received her Bachelor's degree in Economics from Tecnol gico de Monterrey and a Master's degree in Statistics from Oklahoma State University.
- In connection with her employment with the Company and appointment as the Company's Chief Financial Officer, the Company entered into an employment agreement with Ms. Grant-Huerta (the "Employment Agreement"), which sets forth the terms of Ms. Grant-Huerta's employment with the Company.
- Pursuant to the Employment Agreement, Ms. Grant-Huerta will be entitled to receive an annual base salary of $450,000 and will be eligible to earn an annual discretionary bonus of 40% of her then-current annual base salary.
Departing: Robert Lally, Senior Vice President, effective 2026-07-22
On June 22, 2026, Robert Lally, our Senior Vice President of Finance and Operations and principal accounting officer, provided notice of his resignation, effective July 22, 2026.
- Mr. Lally's resignation was not due to any disagreement with the Company.
- We plan to conduct a search for Mr. Lally's replacement.
Tools for this story
Each opens in a new tab, filled in for ImageneBio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.